查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2106728

小分子藥物合約研發生產機構 (CDMO) 的成長機會：全球，2026-2031 年

Growth Opportunities in Small-Molecule Contract Development and Manufacturing Organizations, Global, 2026-2031
出版日期: | 出版商: Frost & Sullivan | 英文 97 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

由於分子複雜性日益增加、專利到期、成本壓力以及確保穩健的藥品供應鏈的策略需求，全球小分子CDMO產業正經歷結構性轉型。市場需求正從大規模生產的通用學名藥轉向高活性原料藥（HPAPI）、抗體藥物複合體（ADC）有效載荷和連接子、複雜口服固體製劑以及無菌注射劑等領域的專業研發和生產能力。在從研發到商業化階段持續外包的推動下，小分子CDMO市場預計將以中等個位數的複合年成長率穩步成長至2031年，這反映了該行業在基礎治療和創新療法領域持續發揮的關鍵作用。

在整個生態系統中，地緣政治格局重組、供應鏈自主化、監管力度加大、永續性要求以及技術創新等多重策略挑戰正在重塑競爭動態。贊助公司越來越期望合約研發生產機構（CDMO）能夠提供快速的技術轉移、先進的工藝科學、靈活的小批量和後期生產能力、可靠的監管合規性以及地域分散的製造地。高活性藥物成分（HPAPI）、抗體偶聯藥物（ADC）相關化學合成以及無菌填充和表面處理工程的生產能力持續受限，推動了北美和歐洲的投資加速成長。同時，亞太地區的公司正透過規模化生產、成本競爭力以及逐步進入監管嚴格的供應領域，不斷鞏固自身地位。

本研究為CDMO企業指明了幾個具有重大影響的成長機遇，包括拓展針對癌症治療管線的高活性藥物成分（HPAPI）和抗體偶聯藥物（ADC）有效載荷連接子的能力，實現無菌灌裝和包裝基礎設施的現代化和自動化，開展顆粒工程、溶解度提升和複雜口服固體製劑的運作模式，以提高固體製劑的運作模式，以提高固體製劑的標準和標準的標準結構可提高固體製劑。積極投資於這些能力、建立長期產能夥伴關係並提供從研發到商業化的一體化平台的CDMO企業，將最有可能實現高速成長。對於製藥企業、投資者和相關人員而言，本研究的發現為在日益策略化和更具韌性的小分子藥物生產環境中創造價值提供了清晰的藍圖。

調查期間為2023年至2031年，其中2025年為基準年，2026年至2031年為預測期。市場區隔如下：

  • 產品種類：藥物活性成分（包括原料藥、高活性藥物成分及中間體）及成品（口服固態、液體製劑、半固態、注射劑等）
  • 服務類型：臨床和商業化生產
  • 區域：北美、歐洲、亞太地區、拉丁美洲和加勒比海地區、中東和非洲

分析和細分範圍

  • 分析範圍
  • 分割

策略要務

  • 為什麼經濟成長變得越來越困難？
  • The Strategic Imperative 8 TM
  • 小分子CDMO產業三大策略要務的影響

成長機會分析

  • 製藥業：小分子藥物的收入、預測和市場佔有率
  • 製藥業：股票報酬和波動趨勢
  • 製藥業資金籌措趨勢
  • 製藥業：早期資金籌措和許可趨勢
  • 製藥業：2025 年併購趨勢
  • 專利到期及其對CDMO的影響
  • 按治療領域分類的藥品銷售額成長
  • 小分子治療領域：發展與成熟曲線
  • 專業小分子藥物研發管線
  • CDMO需求波動及產能管理趨勢
  • 成長促進因素
  • 抑制生長的因素
  • 影響小分子CDMO產業的全球趨勢
  • 影響小分子CDMO產業的產業趨勢
  • 經營模式：在以服務為主的收入模式市場中進行選擇性演進
  • 低分子量CDMO夥伴關係中的系統性責任分擔模式
  • 定價模式的吸引力
  • 合作夥伴關係的成功標準

競爭環境

  • 競爭環境
  • 主要競爭對手
  • 第一層：競爭策略
  • 第二層：競爭策略
  • 第三層：競爭策略
  • 第四層：競爭策略
  • 第五層：競爭策略

產品類型分析：活性成分（API）

  • 非專利API
  • 領先的 API
  • API：M&A
  • API：擴大生產能力
  • API：投資

產品類型分析：最終配方（FDF）

  • 口服
  • 口服藥物：併購與投資
  • 口服藥物：擴大生產能力
  • 液體和半固態製劑
  • 液體和半固態製劑：併購和投資
  • 液體和半固態製劑：擴大生產能力
  • 注射藥物
  • 注射劑：併購與投資
  • 注射劑：擴大生產能力
  • 其他
  • 其他：併購和投資
  • 其他：擴大生產能力

按服務類型分析

  • 臨床
  • 商業的

區域分析

  • 北美洲
  • 北美：值得關注的投資機會
  • 各國具體投資趨勢
  • 歐洲
  • 亞太地區
  • 拉丁美洲和加勒比海地區
  • 中東和非洲

成長機會整體情況

  • 成長機會 1：抗體藥物複合體(ADC) 的高活性藥物成分 (HPAPI)、有效載荷和連接子的整合生產
  • 成長機會2：高附加價值注射劑的無菌填充及包裝生產能力
  • 成長機會3：複雜口服固體製劑製劑的一體化FDF（最終製劑）生產能力

附錄與未來計劃

  • 成長機會的益處和影響
  • 未來計劃
  • 圖表清單
  • 免責聲明
簡介目錄
Product Code: M1K4-52

The global small-molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high-volume commodity generics toward specialized development and manufacturing capabilities in high-potency APIs (HPAPIs), antibody-drug conjugate (ADC) payloads and linkers, complex oral solids, and sterile injectable products. Supported by sustained outsourcing across development and commercial stages, the small-molecule CDMO market is projected to grow at a steady mid-single-digit CAGR through 2031, reflecting the sector’s continued relevance in both essential and innovative therapies.

Across the ecosystem, multiple strategic imperatives—including geopolitical realignment, supply chain sovereignty, regulatory tightening, sustainability mandates, and technology disruption—are reshaping competitive dynamics. Sponsors increasingly expect CDMOs to offer rapid tech transfer, advanced process science, flexible small-batch and late-stage capacity, regulatory reliability, and geographically diversified manufacturing footprints. Capacity constraints persist in HPAPI manufacturing, ADC-related chemistries, and aseptic fill-finish, driving accelerated investment in North America and Europe, while Asia-Pacific players continue to strengthen their position through scale, cost competitiveness, and gradual movement into more regulated supply segments.

The study identifies several high-impact growth opportunities for CDMOs, including expansion of HPAPI and ADC payload-linker capabilities aligned with oncology pipelines; modernization and automation of sterile fill-finish infrastructure; integration of particle engineering, solubility enhancement, and continuous manufacturing for complex oral solids; and adoption of digital, ESG-aligned operating models that enhance transparency and execution reliability. CDMOs that proactively invest in these capabilities, secure long-term capacity partnerships, and offer integrated development-to-commercial platforms will be best positioned to capture premium growth. For pharmaceutical sponsors, investors, and policy stakeholders, the findings provide a clear roadmap for value creation in an increasingly strategic and resilience-driven small-molecule manufacturing landscape.

The study period is 2023 to 2031, with 2025 as the base year and 2026 to 2031 as the forecast period. Market segmentation is by:

  • Product Type: Active pharmaceutical ingredients (APIs, including HPAPIs and intermediates) and finished dosage formulations (oral solids, liquids, semi-solids, injectables, others)
  • Service Type: Clinical and commercial manufacturing
  • Region: North America, Europe, APAC, Latin America & the Caribbean, and the Middle East & Africa

Scope and Segmentation

  • Scope of Analysis
  • Segmentation

Strategic Imperatives

  • Why is it Increasingly Difficult to Grow?
  • The Strategic Imperative 8TM
  • The Impact of the Top 3 Strategic Imperatives on the Small-Molecule CDMO Industry

Growth Opportunity Analysis

  • Pharmaceutical: Small-Molecule Revenue Forecast and Share
  • Pharmaceutical Industry: Equity Returns and Volatility Trends
  • Pharmaceutical Funding Trends
  • Pharmaceutical Industry: Early-Stage Funding and Licensing Activity
  • Pharmaceutical Industry: M&A Activity in 2025
  • Patent Expiries and Implications for CDMOs
  • Pharma Revenue Growth by Modality
  • Small-Molecule Modalities: Development and Maturity Curve
  • Specialty Small-Molecule Pipeline
  • CDMO Demand Volatility and Capacity Management Dynamics
  • Growth Drivers
  • Growth Restraints
  • Global Trends Impacting the Small-Molecule CDMO Industry
  • Industry Trends Impacting the Small-Molecule CDMO Industry
  • Business Model: Selective Evolution within a Fee-for-Service Dominated Market
  • Structured Accountability Models in Small-Molecule CDMO Partnerships
  • Attractiveness of Pricing Models
  • Collaboration Success Criteria

Competitive Environment

  • Competitive Environment
  • Key Competitors
  • Tier I: Competitive Strategies
  • Tier II: Competitive Strategies
  • Tier III: Competitive Strategies
  • Tier IV: Competitive Strategies
  • Tier V: Competitive Strategies

Analysis by Product Type- Active Pharmaceutical Ingredient (API)

  • Generic API
  • Innovator API
  • API: M&As
  • API: Capacity Expansions
  • API: Investments

Analysis by Product Type: Finish Dosage Form (FDF)

  • Oral
  • Oral: M&As and Investments
  • Oral: Capacity Expansions
  • Liquids and Semi-Solids
  • Liquids and Semi-Solids: M&As and Investments
  • Liquids and Semi-Solids: Capacity Expansions
  • Injectables
  • Injectables: M&As and Investments
  • Injectables: Capacity Expansions
  • Others
  • Others: M&As and Investments
  • Others: Capacity Expansions

Analysis by Service Type

  • Clinical
  • Commercial

Analysis by Region

  • North America
  • North America: Notable Investments
  • Investment Flow by Country
  • Europe
  • Asia-Pacific
  • Latin America and Caribbean
  • The Middle East and Africa

Growth Opportunity Universe

  • Growth Opportunity 1: Integrated HPAPI, Payload, and Linker Manufacturing for Antibody-Drug Conjugates
  • Growth Opportunity 2: Sterile Fill-Finish Capacity for High-Value Injectables
  • Growth Opportunity 3: Integrated FDF Capabilities for Complex Oral Solids

Appendix & Next Steps

  • Benefits and Impacts of Growth Opportunities
  • Next Steps
  • List of Exhibits
  • Legal Disclaimer